About Cochlear (ASX: COH)
Cochlear Limited develops and sells implantable hearing solutions for children and adults across markets worldwide. The company's core business spans cochlear implant systems, sound processor upgrades, bone conduction systems, and related accessories, serving patients through a broad portfolio of hardware and software hearing technologies.
Its product range includes the Nucleus family of offerings, covering Nucleus sound processors, Nucleus implants, and a smart bimodal hearing solution, alongside the Baha range of bone conduction products, which encompasses the Baha 6 Max sound processor and the Baha implant. Complementary accessories such as wireless devices and Nucleus water-safe accessories round out the portfolio. Founded in 1981, Cochlear is headquartered in Sydney, Australia.
MFAM Research
- [BUY] Cochlear (ASX: COH) – Oversold In TurmoilMay 7, 2025Cochlear (ASX: COH) is one of the world’s leading health technology firms with global dominance in the internal and external hearing aid space. The stock has reacted sharply to tariff concerns and its impact on the company along with cost overruns and disappointing growth in some operating segments. However, we believe the company presents excellent […]
Latest Announcements
- Cochlear (ASX: COH) – Cochlear FY26 Full Year ResultsAugust 18, 2026Cochlear Limited’s FY26 results delivered underlying net profit of $322 million, up 22% year on year, achieving the upper end of revised guidance despite a challenging operating environment. Sales revenue reached $2.3 billion, representing 2% growth in constant currency with a notably stronger second half expanding 6%, signalling momentum heading into the new financial year. […]
- Cochlear (ASX: COH) – Reports FY26 Full Year ResultsAugust 18, 2026Cochlear Limited delivered underlying net profit of $322 million in FY26, achieving the upper end of revised guidance despite headwinds including flat cochlear implant revenue, lower gross margins, and foreign exchange pressures. Sales revenue increased 2 percent in constant currency to $2.3 billion, though the underlying net profit declined 20 percent in constant currency compared […]
- Cochlear (ASX: COH) – Cochlear Files 2023 Annual ReportAugust 18, 2026Cochlear Limited has released its FY2026 Annual Report, providing stakeholders with a comprehensive overview of the hearing implant specialist’s strategy and performance for the financial year ended 30 June 2026. The timing of the report follows the company’s established practice of detailed annual disclosure, offering investors and analysts an opportunity to assess strategic execution and […]
- Cochlear (ASX: COH) – Files Appendix 4E Financial StatementAugust 18, 2026Cochlear Limited reported flat sales revenue of $2,343.4 million for the financial year ended 30 June 2026, compared with $2,347.6 million in the prior year. Statutory net profit collapsed 62% to $147.3 million from $388.9 million, a dramatic decline that appears disconnected from revenue stability. The gap between flat sales and sharply lower profits signals […]
- Cochlear (ASX: COH) – FY26 Earnings Guidance Reduced Amid Trading ChallengesApril 22, 2026Cochlear Limited has reduced its FY26 underlying net profit guidance to $290-330 million, down from previous expectations, citing softer-than-expected trading conditions in developed markets and heightened uncertainty from Middle Eastern conflicts. The announcement, made on 22 April 2026, represents a material reassessment of the company’s earnings trajectory and reflects a confluence of operational and macroeconomic […]
Financial Summary
Price History
Related Stocks
| Same Industry — Healthcare | Same Sub-Industry — Medical Devices |
|---|---|